全文获取类型
收费全文 | 7533篇 |
免费 | 290篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 111篇 |
妇产科学 | 51篇 |
基础医学 | 412篇 |
口腔科学 | 36篇 |
临床医学 | 509篇 |
内科学 | 1981篇 |
皮肤病学 | 15篇 |
神经病学 | 128篇 |
特种医学 | 315篇 |
外科学 | 3522篇 |
综合类 | 65篇 |
预防医学 | 86篇 |
眼科学 | 21篇 |
药学 | 96篇 |
1篇 | |
中国医学 | 7篇 |
肿瘤学 | 475篇 |
出版年
2024年 | 3篇 |
2023年 | 606篇 |
2022年 | 713篇 |
2021年 | 874篇 |
2020年 | 721篇 |
2019年 | 343篇 |
2018年 | 349篇 |
2017年 | 259篇 |
2016年 | 278篇 |
2015年 | 297篇 |
2014年 | 708篇 |
2013年 | 572篇 |
2012年 | 259篇 |
2011年 | 96篇 |
2010年 | 349篇 |
2009年 | 325篇 |
2008年 | 91篇 |
2007年 | 115篇 |
2006年 | 121篇 |
2005年 | 59篇 |
2004年 | 53篇 |
2003年 | 39篇 |
2002年 | 71篇 |
2001年 | 52篇 |
2000年 | 49篇 |
1999年 | 79篇 |
1998年 | 89篇 |
1997年 | 25篇 |
1996年 | 47篇 |
1995年 | 32篇 |
1994年 | 34篇 |
1993年 | 16篇 |
1992年 | 9篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 10篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 12篇 |
1985年 | 5篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1978年 | 7篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1972年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有7848条查询结果,搜索用时 15 毫秒
11.
12.
《The American journal of medicine》2022,135(7):879-888.e3
ObjectivesClinical trials have shown a beneficial effect from biological disease-modifying antirheumatic drugs (bDMARDs) on hand or axial bone loss in patients with rheumatoid arthritis; however, it is unclear if this translates to a reduced fracture risk. We investigated the effect of bDMARDs on osteoporotic fracture risk compared to no biological treatment in rheumatoid arthritis.MethodsA cohort of patients with rheumatoid arthritis aged 18+ from DANBIO was linked to population-based health registries in Denmark (2006-2016). Adopting a prevalent new-user design, we matched bDMARD users to bDMARD-naïve patients using time-conditional propensity scores. The risk of incident osteoporotic fractures (including hip, vertebrae, humerus, and forearm) was estimated among the matched patients by Cox proportional hazards models.ResultsOut of 24,678 patients with rheumatoid arthritis, 4265 bDMARD users were matched to the same number of bDMARD-naïve patients (mean age 56.2 years, 74% female). During follow-up, 229 osteoporotic fractures occurred among bDMARD users and 205 fractures among bDMARD-naïve patients (incidence rates 12.1 and 13.0 per 1000 person-years, respectively). The use of bDMARDs was not associated with a reduced risk of osteoporotic fractures among patients with rheumatoid arthritis (hazard ratio 0.97, 95% confidence interval 0.78-1.20), compared with no biological treatment. The risk estimates were similar for all osteoporotic fracture sites.ConclusionWe found no independent beneficial effect from using bDMARDs on reducing the risk of osteoporotic fractures in patients with rheumatoid arthritis. 相似文献
13.
14.
Mediastinal teratoma rarely causes pericarditis. We report a case of a 22-year-old young female admitted to the emergency department for inspiratory chest pain and fever with severe pericardial effusion, unexepectable the cause of pericarditis was a mediastinal teratoma. 相似文献
15.
16.
17.
18.
19.
《Current problems in cardiology》2022,47(12):101367
Percutaneous balloon mitral valvuloplasty (PBMV) is primarily performed for rheumatic mitral stenosis (MS). Therefore, limited data exist on PBMV in countries with a low incidence of rheumatic disease. Using the Nationwide Readmission Database, we examined trends in in-hospital mortality and 30-day readmission among patients who received PBMV for rheumatic and non-rheumatic MS. We also examined the change in 90-day hospitalization rate before vs after PBMV. Between 2016 and 2019, there were 1109 hospitalizations in which patients received PBMV for rheumatic (n = 955, 86.1%) vs non-rheumatic MS (n = 154, 13.9%). The all-cause in-hospital mortality for rheumatic and non-rheumatic MS did not change over time (0.9% → 2.0%, P = 0.94, and 5.9% → 9.5%, P = 0.09 respectively). Similarly, the 30-day readmission for patients with rheumatic and non-rheumatic MS did not change over time (12.4% → 9.9%, P = 0.26, and 4.4% → 10.5%, P = 0.30, respectively). The 90-day all-cause hospitalization rate remained the same before vs after PBMV for rheumatic and non-rheumatic MS (25.5% → 21.8%; P = 0.14, and 24.0% → 33.7%; P = 0.19, respectively). Although no statistically significant change was noted over time for trends in in-hospital mortality, 30-day readmission, or even in the change in 90-day all-cause hospitalizations before and after PBMV for both types of MS, among those with non-rheumatic MS, there was a signal of an increase in the in-hospital mortality, and 30-day readmission, even more, there was 29% relative increase in 90-day hospitalizations after PBMV. Future studies are needed to examine the role of PBMV in patients with non-rheumatic MS. 相似文献
20.
BackgroundPeriodontitis has been associated with coronary artery disease, but the impact of a periodontal treatment on the endothelial function of patients with a recent ST-segment elevation myocardial infarction (STEMI) was not investigated.MethodsRandomized controlled trial (NCT02543502). Patients admitted between August 2012 and January 2015 were included. Patients were screened during the index hospitalization for STEMI, and those with severe periodontal disease were randomized 2 weeks later to periodontal treatment or to control. The primary endpoint of this trial was the between group difference in the variation of flow-mediated vasodilation (FMD) in the brachial artery assessed by ultrasound from baseline to the 6-month follow-up. Secondary outcomes were cardiovascular events, adverse effects of periodontal treatment and inflammatory markers.ResultsBaseline characteristics were balanced between patients in the intervention (n = 24) and control groups (n = 24). There was a significant FMD improvement in the intervention group (3.05%; p = .01), but not in the control group (−0.29%; p = .79) (p = .03 for the intergroup comparison). Periodontal treatment was not associated with any adverse events and the inflammatory profile and cardiovascular events were not significantly different between both groups.ConclusionsTreatment of periodontal disease improves the endothelial function of patients with a recent myocardial infarction, without adverse clinical events. Larger trials are needed to assess the benefit of periodontal treatment on clinical outcomes.Clinical trial registrationNCT02543502 (https://clinicaltrials.gov/ct2/show/NCT02543502?term=NCT02543502&rank=1). 相似文献